Mental StressNCT06345573
Heart-brain-axis and Psychosocial Stress
An observational study of Mental Stress and Myocardial Ischemia, run by University of Zurich at 1 site in Switzerland.
Trial summary
The main study objective is to prospectively determine the influence of sex-related risk factors and psychosocial variables on neuronal stress responses and myocardial perfusion in a population of 64 female and male individuals 50-75 years of age and free of cardiovascular disease. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Mental Stress, Myocardial Ischemia, Sex Role
- What is being tested?
- Mental stress
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 64 participants
- Where
- 1 siteSwitzerland
- Study dates
- 11 Oct 2021to 20 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: We included healthy volunteers aged between 50-75 years old, post-menopausal in the case of women, recruited mainly in Switzerland.
Who may be able to join
- Women and men that are between 50-75 years of age
- Post-menopausal status in women
- Normal body weight (BMI<30kg/m2)
- Non-smoker or not smoking since ≥ 5 years or occasional smokers.
Who cannot join
- Written informed consent was not provided
- History of arterial hypertension
- History of diabetes
- History of cardiovascular disease
- History of neurological disorders
- History of cancer (unless considered in remission since at least 5 years and not having necessitated a systemic chemotherapy and/or a brain radiotherapy)
- Use of steroids interfering with biomarker levels
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich
Zurich, Canton of Zurich, 8091
About this study
Official title: Sex Differences in Heart-brain Crosstalk - Role of Psychosocial Stress
The main study objective is to prospectively determine the influence of sex-related risk factors and psychosocial variables on neuronal stress responses and myocardial perfusion in a population of 64 female and male individuals 50-75 years of age and free of cardiovascular disease.
Read the detailed description
The main objective of the project is to prospectively determine the influence of sex on amygdalar metabolic activity and myocardial perfusion in a population of healthy postmenopausal women and aged men under acute psychosocial stress conditions.
The primary hypothesis of the study is that women experience disproportionate amygdalar metabolic activity and reduced myocardial perfusion in response to psychosocial stress compared to men.
This project is a monocentric prospective observational study involving hybrid positron emission tomography/magnetic resonance (PET/MR) imaging as well as the collection of biological samples in healthy individuals aged 50-75 years (postmenopausal women, and men). To inflict acute psychosocial stress, the investigators applied the Montreal Imaging Stress Test (MIST) when the participants were inside the PET/MR scanner and the Trier Social Stress Test (TSST) when the participants were outside the PET/MR scanner. Both the TSST and the MIST are standardized tests and are widely applied to provoke reliable biological stress responses in a laboratory setting. No follow-up study is planned. At inclusion, individuals have been interviewed and health data have been collected through questionnaires. In addition, biological samples, including blood, nail and saliva have been collected. Volunteers underwent myocardial blood flow (MBF) and cerebral perfusion imaging using ammonia (13NH3)-PET, as well as functional imaging using magnetic resonance imaging (MRI), both routinely used imaging techniques. 13NH3-PET/MR has been conducted at rest and under stress (MIST). Subsequently, the study participants underwent a TSST, followed by whole body metabolic imaging with fluor-18-deoxyglucose (18F-FDG)-PET/MRI, allowing to study brain and bone marrow metabolism, among other parameters. In parallel, the heart rate response (HRR) has been monitored throughout the study and catecholamines were collected at baseline and after stress to assess the autonomic influence on the heart. The total radiation exposure was below 5 mSv.
In detail, each participant was asked to complete questionnaires to assess their psychometric baseline characteristics at the study visit.
Two blood samples were collected from a peripheral intravenous catheter, at the beginning of the study and the end of the TSST. Blood glucose levels were measured using a finger prick. In addition, saliva samples of approximately 1 mL each were taken at different time points, notably before and after each of the mental stress tests. Nail samples were collected by clipping nails from the fingers and/or toes.
All biological samples from the participants were immediately processed to allow sample conservation.
Project data and samples were handled with the uttermost discretion and only accessible to authorized personnel. On project-specific documents, participants are only identified by a unique participant number. Coded data were used and the participant identification list is only accessible by the investigators. Data is protected from unauthorized or accidental disclosure, alteration, deletion, copying, and theft by using the built-in mechanisms of Redcap®. Biological material in this project is not identified by participant name but by a unique participant number.
Participants were asked to fast for at least 2.5 hours prior to the study visit and refrain from strong physical activity for at least 24 hours. All study participants underwent serial imaging on a dedicated hybrid PET/MR scanner (GE Healthcare) using 13N-NH3 and 18F-FDG as validated tracers, according to daily clinical routine. Whole-body (18F-FDG) or brain and heart (13-NH3) MRI were recorded simultaneously with all PET scan acquisitions. Beginning with an intravenous bolus administration of 200 MBq of 13N-NH3, serial dynamic and static PET images were acquired for 30 minutes. In parallel, subjects underwent the Control (rest) part of the MIST (mathematical task, inside the scanner). A second dose of 400 MBq of 13N-NH3 was given, and images were recorded in the same acquisition sequence for 30 minutes, in parallel to the Stress part of the MIST.
After a break, all individuals were injected with 150 MBq of 18F-FDG, followed by a TSST outside of the scanner. During the first part of the TSST, a panel of two to three judges (trained staff), equipped with a video camera, ask the participant to prepare a 5-minute presentation. To do that, participants can use paper and pen but must hand out their notices at the beginning of the presentation. During the 5-minute presentation, the judges observe the participants without giving any comments or facial expressions. The participants are asked to continue if they stop before the entire 5 minutes run out. For the second part of the TSST, participants undergo a mental arithmetic task during which they are asked to count backward from 1022 in steps of 11. Subsequently, participants were allowed to rest in a designated separate dark room (rest phase), and the 18F-FDG-PET scan was performed ca. 60 min after tracer injection to assess metabolic activity in the brain, according to routine procedures at the Department of Nuclear Medicine of the University Hospital Zurich. Heart rate and blood pressure were recorded at baseline and throughout the procedure.
The procedure from the initial scan to the end of the final scan takes about 3.5 hours. Together with the 2 hours of preparation, participants spent about 5.5 hours on the study in total.
- Conditions
- Mental Stress, Myocardial Ischemia, Sex Role, Gender
- Being tested
- Mental stress
- Medical subject headings
- Stress, Psychological, Myocardial Ischemia, Coitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mental stressBehavioural
Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
| Study group | Role | What they receive |
|---|---|---|
| Female Sex | Healthy volunteer women aged between 50-75 years old, in post-menopausal status. Receives: Behavioral: Mental stress | |
| Male Sex | Healthy volunteer men aged between 50-75 years old. Receives: Behavioral: Mental stress |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amygdala-to-cerebellum ratio of glycolytic metabolic activities (SUV/SUV)
Sex differences in the stress-related neural activity (SNA) assessed by 18F-FDG-PET and defined as the amygdala metabolic activity (AmygA, expressed as standard uptake value, SUV) corrected to the metabolic activity of the cerebellum (expressed as SUV), following the Trier Social Stress Test. The higher the AmygA/(cerebellum activity) ratio, the higher the SNA (no threshold for normality)
Measured: 11-10-2021 to 20-11-2023
Difference between the rest and stress amygdala-to-cerebellum perfusion ratios (kBq/kBq)
Sex differences in the amygdala perfusion between rest and stress, assessed by 13N-NH3-PET and defined as the amygdala perfusion (AmygP, expressed as kiloBecquerel, kBq) corrected to the perfusion of the cerebellum (expressed as kBq), following the Montreal Imaging Stress Task. The higher the magnitude of the AmygP/(Cerebellum perfusion) modification at stress compared to rest, the higher the amygdala response to mental stress (no threshold for normality)
Measured: 11-10-2021 to 20-11-2023
Myocardial flow reserve (MFR, no unit)
Sex differences in myocardial flow reserve (MFR) as determined by 13N-NH3-PET, during the Montreal Imaging Stress Task. MFR is defined as the ratio between MBF at stress and MBF at rest (no unit). The higher the MFR, the higher the myocardial perfusion modification during the stress task (no threshold).
Measured: 11-10-2021 to 20-11-2023
Secondary outcomes (24)
Amygdala-to-vmPFC ratio of glycolytic metabolic activities (SUV/SUV)
Sex differences in the stress-related neural activity (SNA) assessed by 18F-FDG-PET and defined as the amygdala metabolic activity (AmygA, expressed as standard uptake value, SUV) corrected to the metabolic activity of the ventromedial prefrontal cortex vmPFC (expressed as SUV), following the Trier Social Stress Test. The higher the AmygA/(vmPFC activity) ratio, the higher the SNA (no threshold for normality)
Measured: 11-10-2021 to 20-11-2023
Difference between the rest and stress amygdala-to-vmPFC perfusion ratios (kBq/kBq)
Sex differences in the amygdala perfusion between rest and stress, assessed by 13N-NH3-PET and defined as the amygdala perfusion (AmygP, expressed as kiloBecquerel, kBq) corrected to the perfusion of the ventromedial prefrontal cortex (vmPFC, expressed as kBq), following the Montreal Imaging Stress Task. The higher the magnitude of the AmygP/(vmPFC perfusion) modification at stress compared to rest, the higher the amygdala response to mental stress (no threshold for normality)
Measured: 11-10-2021 to 20-11-2023
Myocardial blood flow (MBF) at rest (mL/g/min)
Sex differences in myocardial blood flow (MBF, in mL/g/min) as determined by 13N-NH3-PET, during the control mode of the Montreal Imaging Stress Task. The higher the MBF, the higher the myocardial perfusion (no threshold).
Measured: 11-10-2021 to 20-11-2023
Myocardial blood flow (MBF) at stress (mL/g/min)
Sex differences in myocardial blood flow (MBF, in mL/g/min) as determined by 13N-NH3-PET, during the stress mode of the Montreal Imaging Stress Task. The higher the MBF, the higher the myocardial perfusion (no threshold).
Measured: 11-10-2021 to 20-11-2023
Heart-rate response (HRR, no unit)
Sex differences in the heart rate response (HRR), a surrogate for cardiac sympathetic activity, following each of the Montreal Imaging Stress Task and the Trier Social Stress Test. The HRR is defined as follows: HRR = ((Heart Rate at Stress) - (Heart Rate at Rest)/(Heart Rate at Rest)). The higher the HRR, the higher the cardiac sympathetic response to stress.
Measured: 11-10-2021 to 20-11-2023
Salivary cortisol (mol/L)
Sex differences in the salivary cortisol response, a surrogate marker for the hypothalamic-pituitary-axis (HPA), to each of the Montreal Imaging Stress Task and the Trier Social Stress Test. The higher the cortisol increase, the higher the HPA response (no threshold).
Measured: 11-10-2021 to 20-11-2023
Noradrenaline (mL/min)
Sex differences in the blood noradrenaline increase (mL/min) following the Trier Social Stress Task.
Measured: 11-10-2021 to 20-11-2023
Adrenaline (mL/min)
Sex differences in the blood adrenaline increase (mL/min) following the Trier Social Stress Task.
Measured: 11-10-2021 to 20-11-2023
Dopamine (mL/min)
Sex differences in the blood dopamine increase (mL/min) following the Trier Social Stress Task.
Measured: 11-10-2021 to 20-11-2023
Spleen metabolic activity (SUV)
Sex differences in the spleen metabolic activity, a surrogate for systemic inflammation, following the Trier Social Stress Test, as assessed by 18F-FDG-PET, and expressed in standard uptake value (SUV). The higher the spleen SUV, the higher systemic inflammation.
Measured: 11-10-2021 to 20-11-2023
Bone marrow metabolic activity (SUV)
Sex differences in the bone marrow metabolic activity, a surrogate for systemic inflammation, following the Trier Social Stress Test, as assessed by 18F-FDG-PET, and expressed in standard uptake value (SUV). The higher the bone marrow SUV, the higher systemic inflammation.
Measured: 11-10-2021 to 20-11-2023
Aorta metabolic activity (SUV)
Sex differences in the thoracic aorta metabolic activity, a surrogate for aortic inflammation, following the Trier Social Stress Test, as assessed by 18F-FDG-PET, and expressed in standard uptake value (SUV). The higher the aorta SUV, the higher aorta inflammation.
Measured: 11-10-2021 to 20-11-2023
Left ventricular ejection fraction (LVEF, %)
Sex differences in the left ventricular ejection fraction (LVEF, %) following the control and stress phases of the Montreal Imaging Stress Task.
Measured: 11-10-2021 to 20-11-2023
C-reactive protein (CRP, mg/L)
Sex differences in C-reactive protein (CRP, in mg/L) collected at baseline and after the Trier Social Stress Test. The higher the CRP, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Interleukin-2 (IL-2, pg/mL)
Sex differences in Interleukin-2 (IL-2), collected at baseline and after the Trier Social Stress Test. The higher the IL-2, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Interleukin-4 (IL-4, pg/mL)
Sex differences in Interleukin-4 (IL-4) collected at baseline and after the Trier Social Stress Test. The higher the IL-4, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Interleukin-6 (IL-6, pg/mL)
Sex differences in Interleukin-6 (IL-6) collected at baseline and after the Trier Social Stress Test. The higher the IL-6, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Interleukin-8 (IL-8, pg/mL)
Sex differences in Interleukin-8 (IL-8) collected at baseline and after the Trier Social Stress Test. The higher the IL-8, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Interleukin-10 (IL-10, pg/mL)
Sex differences in Interleukin-10 (IL-10) collected at baseline and after the Trier Social Stress Test. The higher the IL-10, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Tumor necrosis factor (TNF, pg/mL)
Sex differences in Tumor necrosis factor (TNF, pg/mL) collected at baseline and after Trier Social Stress Test. The higher the TNF, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Matrix metalloproteinase-9 (MMP9, pg/mL)
Sex differences in Matrix metalloproteinase-9 (MMP9, pg/mL), collected at baseline and after Trier Social Stress Test. The higher the MMP9, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Monocyte Chemoattractant Protein-1 (MCP1, pg/mL)
Sex differences in Monocyte Chemoattractant Protein-1 (MCP1, pg/mL), collected at baseline and after Trier Social Stress Test. The higher the MCP1, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Vascular Cell Adhesion Molecule (VCAM)
Sex differences in Monocyte Chemoattractant Protein-1 (MCP1, pg/mL), collected at baseline and after Trier Social Stress Test. The higher the VCAM, the higher the inflammation.
Measured: 11-10-2021 to 20-11-2023
Gender score questionnaire
Sex differences in the self-perceived gender identity on a 0-to-100 scale, lower scores indicating a more pronounced "male gender" identity, higher scores indicating a more pronounced "female gender" identity. In addition to stratifying the analysis by sex, the role of gender on the results will be explored.
Measured: 11-10-2021 to 20-11-2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2024
- Study start11 Oct 2021
- Primary completion20 Nov 2023
- Study completion20 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mental StressStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cathérine Gebhard, Professor, Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06345573
- Sponsor's protocol ID
- BASEC 2020-02922
- Status last verified
- May 2026
- First submitted
- 5 Mar 2024
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sex Differences in Heart-brain Crosstalk - Role of Psychosocial Stress
- ClinicalTrials.gov ID
- NCT06345573
- Acronym / sponsor ID
- BASEC 2020-02922
- Conditions
- Mental Stress, Myocardial Ischemia, Sex Role, Gender
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 11 Oct 2021 (actual)
- Primary completion
- 20 Nov 2023 (actual)
- Study completion
- 20 Nov 2024 (actual)
- First posted
- 3 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main study objective is to prospectively determine the influence of sex-related risk factors and psychosocial variables on neuronal stress responses and myocardial perfusion in a population of 64 female and male individuals 50-75 years of age and free of cardiovascular disease.
Detailed description
The main objective of the project is to prospectively determine the influence of sex on amygdalar metabolic activity and myocardial perfusion in a population of healthy postmenopausal women and aged men under acute psychosocial stress conditions.
The primary hypothesis of the study is that women experience disproportionate amygdalar metabolic activity and reduced myocardial perfusion in response to psychosocial stress compared to men.
This project is a monocentric prospective observational study involving hybrid positron emission tomography/magnetic resonance (PET/MR) imaging as well as the collection of biological samples in healthy individuals aged 50-75 years (postmenopausal women, and men). To inflict acute psychosocial stress, the investigators applied the Montreal Imaging Stress Test (MIST) when the participants were inside the PET/MR scanner and the Trier Social Stress Test (TSST) when the participants were outside the PET/MR scanner. Both the TSST and the MIST are standardized tests and are widely applied to provoke reliable biological stress responses in a laboratory setting. No follow-up study is planned. At inclusion, individuals have been interviewed and health data have been collected through questionnaires. In addition, biological samples, including blood, nail and saliva have been collected. Volunteers underwent myocardial blood flow (MBF) and cerebral perfusion imaging using ammonia (13NH3)-PET, as well as functional imaging using magnetic resonance imaging (MRI), both routinely used imaging techniques. 13NH3-PET/MR has been conducted at rest and under stress (MIST). Subsequently, the study participants underwent a TSST, followed by whole body metabolic imaging with fluor-18-deoxyglucose (18F-FDG)-PET/MRI, allowing to study brain and bone marrow metabolism, among other parameters. In parallel, the heart rate response (HRR) has been monitored throughout the study and catecholamines were collected at baseline and after stress to assess the autonomic influence on the heart. The total radiation exposure was below 5 mSv.
In detail, each participant was asked to complete questionnaires to assess their psychometric baseline characteristics at the study visit.
Two blood samples were collected from a peripheral intravenous catheter, at the beginning of the study and the end of the TSST. Blood glucose levels were measured using a finger prick. In addition, saliva samples of approximately 1 mL each were taken at different time points, notably before and after each of the mental stress tests. Nail samples were collected by clipping nails from the fingers and/or toes.
All biological samples from the participants were immediately processed to allow sample conservation.
Project data and samples were handled with the uttermost discretion and only accessible to authorized personnel. On project-specific documents, participants are only identified by a unique participant number. Coded data were used and the participant identification list is only accessible by the investigators. Data is protected from unauthorized or accidental disclosure, alteration, deletion, copying, and theft by using the built-in mechanisms of Redcap®. Biological material in this project is not identified by participant name but by a unique participant number.
Participants were asked to fast for at least 2.5 hours prior to the study visit and refrain from strong physical activity for at least 24 hours. All study participants underwent serial imaging on a dedicated hybrid PET/MR scanner (GE Healthcare) using 13N-NH3 and 18F-FDG as validated tracers, according to daily clinical routine. Whole-body (18F-FDG) or brain and heart (13-NH3) MRI were recorded simultaneously with all PET scan acquisitions. Beginning with an intravenous bolus administration of 200 MBq of 13N-NH3, serial dynamic and static PET images were acquired for 30 minutes. In parallel, subjects underwent the Control (rest) part of the MIST (mathematical task, inside the scanner). A second dose of 400 MBq of 13N-NH3 was given, and images were recorded in the same acquisition sequence for 30 minutes, in parallel to the Stress part of the MIST.
After a break, all individuals were injected with 150 MBq of 18F-FDG, followed by a TSST outside of the scanner. During the first part of the TSST, a panel of two to three judges (trained staff), equipped with a video camera, ask the participant to prepare a 5-minute presentation. To do that, participants can use paper and pen but must hand out their notices at the beginning of the presentation. During the 5-minute presentation, the judges observe the participants without giving any comments or facial expressions. The participants are asked to continue if they stop before the entire 5 minutes run out. For the second part of the TSST, participants undergo a mental arithmetic task during which they are asked to count backward from 1022 in steps of 11. Subsequently, participants were allowed to rest in a designated separate dark room (rest phase), and the 18F-FDG-PET scan was performed ca. 60 min after tracer injection to assess metabolic activity in the brain, according to routine procedures at the Department of Nuclear Medicine of the University Hospital Zurich. Heart rate and blood pressure were recorded at baseline and throughout the procedure.
The procedure from the initial scan to the end of the final scan takes about 3.5 hours. Together with the 2 hours of preparation, participants spent about 5.5 hours on the study in total.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Female Sex | – | Behavioral: Mental stressHealthy volunteer women aged between 50-75 years old, in post-menopausal status. |
| Male Sex | – | Behavioral: Mental stressHealthy volunteer men aged between 50-75 years old. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- We included healthy volunteers aged between 50-75 years old, post-menopausal in the case of women, recruited mainly in Switzerland.
Key inclusion criteria (4 listed)
- Women and men that are between 50-75 years of age
- Post-menopausal status in women
- Normal body weight (BMI<30kg/m2)
- Non-smoker or not smoking since ≥ 5 years or occasional smokers.
Key exclusion criteria (7 listed)
- Written informed consent was not provided
- History of arterial hypertension
- History of diabetes
- History of cardiovascular disease
- History of neurological disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mental stressTwo consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part). | Behavioural | Female Sex, Male Sex |
Primary outcome
Amygdala-to-cerebellum ratio of glycolytic metabolic activities (SUV/SUV)
Time frame: 11-10-2021 to 20-11-2023
Sex differences in the stress-related neural activity (SNA) assessed by 18F-FDG-PET and defined as the amygdala metabolic activity (AmygA, expressed as standard uptake value, SUV) corrected to the metabolic activity of the cerebellum (expressed as SUV), following the Trier Social Stress Test. The higher the AmygA/(cerebellum activity) ratio, the higher the SNA (no threshold for normality)
Difference between the rest and stress amygdala-to-cerebellum perfusion ratios (kBq/kBq)
Time frame: 11-10-2021 to 20-11-2023
Sex differences in the amygdala perfusion between rest and stress, assessed by 13N-NH3-PET and defined as the amygdala perfusion (AmygP, expressed as kiloBecquerel, kBq) corrected to the perfusion of the cerebellum (expressed as kBq), following the Montreal Imaging Stress Task. The higher the magnitude of the AmygP/(Cerebellum perfusion) modification at stress compared to rest, the higher the amygdala response to mental stress (no threshold for normality)
Myocardial flow reserve (MFR, no unit)
Time frame: 11-10-2021 to 20-11-2023
Sex differences in myocardial flow reserve (MFR) as determined by 13N-NH3-PET, during the Montreal Imaging Stress Task. MFR is defined as the ratio between MBF at stress and MBF at rest (no unit). The higher the MFR, the higher the myocardial perfusion modification during the stress task (no threshold).
24 secondary outcomes
Amygdala-to-vmPFC ratio of glycolytic metabolic activities (SUV/SUV)
Time frame: 11-10-2021 to 20-11-2023
Difference between the rest and stress amygdala-to-vmPFC perfusion ratios (kBq/kBq)
Time frame: 11-10-2021 to 20-11-2023
Myocardial blood flow (MBF) at rest (mL/g/min)
Time frame: 11-10-2021 to 20-11-2023
Myocardial blood flow (MBF) at stress (mL/g/min)
Time frame: 11-10-2021 to 20-11-2023
Heart-rate response (HRR, no unit)
Time frame: 11-10-2021 to 20-11-2023
Salivary cortisol (mol/L)
Time frame: 11-10-2021 to 20-11-2023
Noradrenaline (mL/min)
Time frame: 11-10-2021 to 20-11-2023
Adrenaline (mL/min)
Time frame: 11-10-2021 to 20-11-2023
Dopamine (mL/min)
Time frame: 11-10-2021 to 20-11-2023
Spleen metabolic activity (SUV)
Time frame: 11-10-2021 to 20-11-2023
Bone marrow metabolic activity (SUV)
Time frame: 11-10-2021 to 20-11-2023
Aorta metabolic activity (SUV)
Time frame: 11-10-2021 to 20-11-2023
Left ventricular ejection fraction (LVEF, %)
Time frame: 11-10-2021 to 20-11-2023
C-reactive protein (CRP, mg/L)
Time frame: 11-10-2021 to 20-11-2023
Interleukin-2 (IL-2, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Interleukin-4 (IL-4, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Interleukin-6 (IL-6, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Interleukin-8 (IL-8, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Interleukin-10 (IL-10, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Tumor necrosis factor (TNF, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Matrix metalloproteinase-9 (MMP9, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Monocyte Chemoattractant Protein-1 (MCP1, pg/mL)
Time frame: 11-10-2021 to 20-11-2023
Vascular Cell Adhesion Molecule (VCAM)
Time frame: 11-10-2021 to 20-11-2023
Gender score questionnaire
Time frame: 11-10-2021 to 20-11-2023
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Mental Stress
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cathérine Gebhard, Professor principal investigator
University of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mental Stress and Myocardial Ischemia, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amygdala-to-cerebellum ratio of glycolytic metabolic activities (SUV/SUV) (time frame: 11-10-2021 to 20-11-2023). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.